Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen deal CNBC

Horizon Therapeutics’ stock price plunged more than 17% in premarket trading Tuesday after a report that the Federal Trade Commission is preparing to file a lawsuit to block the biotech company’s $27… [+1727 chars]Read More